TrialGraph: Machine Intelligence Enabled Insight from Graph Modelling of
  Clinical Trials
  A major impediment to successful drug development is the complexity, cost,
and scale of clinical trials. The detailed internal structure of clinical trial
data can make conventional optimization difficult to achieve. Recent advances
in machine learning, specifically graph-structured data analysis, have the
potential to enable significant progress in improving the clinical trial
design. TrialGraph seeks to apply these methodologies to produce a
proof-of-concept framework for developing models which can aid drug development
and benefit patients. In this work, we first introduce a curated clinical trial
data set compiled from the CT.gov, AACT and TrialTrove databases (n=1191
trials; representing one million patients) and describe the conversion of this
data to graph-structured formats. We then detail the mathematical basis and
implementation of a selection of graph machine learning algorithms, which
typically use standard machine classifiers on graph data embedded in a
low-dimensional feature space. We trained these models to predict side effect
information for a clinical trial given information on the disease, existing
medical conditions, and treatment. The MetaPath2Vec algorithm performed
exceptionally well, with standard Logistic Regression, Decision Tree, Random
Forest, Support Vector, and Neural Network classifiers exhibiting typical
ROC-AUC scores of 0.85, 0.68, 0.86, 0.80, and 0.77, respectively. Remarkably,
the best performing classifiers could only produce typical ROC-AUC scores of
0.70 when trained on equivalent array-structured data. Our work demonstrates
that graph modelling can significantly improve prediction accuracy on
appropriate datasets. Successive versions of the project that refine modelling
assumptions and incorporate more data types can produce excellent predictors
with real-world applications in drug development.
